World Sleep Industry ENCYCLOPEDIA

Sleep Microbiome Research Services

6.5.3

Definition, scope, and evidence boundary

Sleep microbiome research services support the study of relationships among sleep, circadian rhythms, and human- or animal-associated microbial communities through research design, specimen and metadata management, laboratory measurement, bioinformatics, statistics, and reporting. Subjects may include bacteria, archaea, fungi, viruses, genes, or metabolic functions from the gut, mouth, nasopharynx, skin, or other sites and may be linked with questionnaires, actigraphy, polysomnography, metabolic measures, and immune data. A microbiome is a community and its functional information, not a fixed list of “good” and “bad” organisms produced by one test.

The provider should distinguish exploratory association, longitudinal observation, intervention, mechanistic work, biomarker development, and product evaluation and state whether it supplies sequencing, bioinformatics, statistics, or an end-to-end workflow. Microbial differences can change with sleep, diet, medication, disease, and daily timing. Association, predicted function, or an animal result alone does not show that microbes caused a sleep disorder and does not directly support a probiotic, diet, fecal microbiota product, or other treatment recommendation. A research report is neither a clinical diagnosis nor a product authorization.

Research question, cohort, and confounding control

The protocol should prespecify the target population, sleep exposure or outcome, microbial site, comparator, time points, primary measure, estimand, and analysis level and explain the role of a cross-sectional, case-control, cohort, crossover, or randomized design. Eligibility and stratification may need to consider age, sex, body size, geography, social factors, comorbidity, infection, recent travel, menstruation or pregnancy, smoking, alcohol, and shift work. Sample size should not be based only on sequencing depth or previously significant taxa; interpersonal variation, repeated measures, batch, expected effect, missingness, and multiplicity matter.

Diet and meal timing, antibiotics, prebiotics and probiotics, laxatives, acid suppression, metformin and other medicines, and bowel frequency and form can influence gut findings. Sleep is also affected by caffeine, alcohol, activity, light, and workday versus free-day schedules. These data should be collected in a time window aligned with the specimen, with the sleep measurement method and version recorded. Important unmeasured or unbalanced confounders belong in the limitations; statistical adjustment alone cannot establish that reverse causality and unmeasured confounding have been removed.

Sampling, preservation, and laboratory design

The sampling plan should fix body site, collection device, date and clock time, interval from sleep and meals, bowel information, stabilizer, transport temperature and duration, storage, freeze–thaw count, and acceptance criteria. Microbial communities vary within people and across the day, so one stool specimen represents neither the entire gut nor necessarily a long-term state; longitudinal questions commonly require repeat sampling. Groups should be randomized or balanced across collection, extraction, library, and sequencing batches so that case status is not perfectly confounded with batch.

Laboratory work should include blank collection, extraction, and library negative controls and a positive control of known composition or a reference material, with technical replicates and external quantitative standards where appropriate. Reagent, environmental, and cross-sample contamination can dominate low-biomass specimens and should be traced from collection through analysis rather than addressed only by deleting familiar taxa afterward. Specimen identity, amount, extraction kit and lot, lysis, nucleic-acid quantity and quality, instrument, operator, and deviations require records. Insufficient, leaking, temperature-excursion, or identity-conflicted specimens should follow predefined quarantine and disposition rules.

Measurement technology and bioinformatics

Amplicon sequencing can describe community structure in a selected marker region, but primer, target region, amplification, and reference databases limit resolution and introduce bias; it is not equivalent to whole-genome function. Shotgun metagenomics can provide greater taxonomic and functional information but remains affected by host DNA, depth, databases, and annotation. Metatranscriptomics, metabolomics, culture, and quantitative PCR answer different questions. Technology should be selected for the primary question, specimen, expected biomass, cost, and validation need, not ranked by name alone.

The bioinformatics workflow should record raw-read checks, adapter removal, quality filtering, denoising or assembly, chimera and host-sequence handling, contamination assessment, taxonomic or functional databases, versions, parameters, and specimen exclusions. Raw and filtered reads, feature tables, taxonomy, and functional annotations should connect through stable specimen identifiers, with code, software environment, and provenance retained. Names, genes, and pathways in reference databases change; an unclassified sequence is not biologically empty, and predicted function is not measured expression or a measured metabolite.

Compositional statistics and interpretation

Microbiome sequencing usually yields relative abundances constrained by library total. A feature’s proportion may increase because other features decreased, not because its absolute amount rose. Analysis should describe filtering, zeros, normalization or transformation, distances, covariates, and multiplicity and choose community-wide, alpha-diversity, beta-diversity, differential-abundance, or longitudinal methods for the question. Rarefaction, proportions, log ratios, and count models carry different assumptions; analysts should not select the most significant result across pipelines. Claims of absolute abundance require an appropriate quantitative design or external standard.

The statistical unit is usually the participant or experimental unit, not each read or taxon. Repeated specimens, households, cages, centers, and batches require model treatment. Reports should give effect sizes, uncertainty, missingness, exclusions, sensitivity analyses, and null findings and distinguish discovery from independent validation. A genus may contain different species and strains, so a taxonomic difference does not automatically reveal function. A network edge is not direct evidence of microbial interaction, and machine-learning classification accuracy is not clinical utility or causal mechanism.

Sleep, circadian timing, and multi-omics integration

The sleep phenotype should identify whether it comes from self-reported duration, diary, questionnaire, actigraphy, home testing, or polysomnography and document time zone, work schedule, sampling phase, recent sleep, and meals. Insomnia symptoms, sleep apnea, duration, stages, fragmentation, and circadian misalignment are different constructs and should not be collapsed into one “sleep quality” variable. Collection time may be a confounder and the central variable of a rhythmicity study. Claims about rhythms require prespecified repeat sampling at adequate times and models appropriate for periodic data.

Microbiome, metabolome, transcriptome, immune, and sleep-physiology data can be aligned with time, specimen, and participant keys, but their coverage, scale, missingness, and batch cannot simply be concatenated. Pathway prediction, mediation analysis, and multi-omics networks generate mechanistic hypotheses that still need independent data, targeted measurements, or experiments. Population association, animal transfer, and in-vitro studies provide different evidence layers. Each link from a microbe-associated metabolite to a human sleep effect should state alternative explanations and limits on extrapolation.

Delivery, governance, and quality oversight

The delivery package may include the protocol, specimen and covariate dictionaries, collection and chain records, batch layout, quality and contamination reports, raw-sequence inventory, feature and annotation tables, bioinformatics provenance, statistical code, figures, and report. Reporting should follow applicable guidance and describe cohort flow, all processing parameters, database versions, control performance, exclusions, batches, effects, and limitations while separating prespecified and exploratory results. Sequence and metadata sharing must follow consent, ethics, privacy, cross-border, and repository rules; removing names may not eliminate identification risk from host genetic or rare-feature information.

Quality oversight should cover staff training, specimen receipt, temperature and inventory, reagent lots, instrument maintenance, control trends, code review, access, backup, defects, and change control. Comparability should be assessed after changes to protocols, reagents, platforms, or databases, and reanalysis should preserve versions instead of silently replacing them. At closeout, specimens and data should be returned, retained, or destroyed under agreement. Quality is shown by a clear question, controlled batches, effective controls, reproducible analysis, protected privacy, and restrained conclusions—not by read count, length of a taxon list, or number of significant associations.